multiple sclerosis news - Search News

Sanofi, Multiple Sclerosis

Bloomberg L.P. · 2d

Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Benzinga.com · 1d

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,

BioTechniques · 2d

Biomarkers for predicting multiple sclerosis progression identified

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.

Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.

The Globe and Mail · 1d

New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection

MedPage Today15h

Women With MS Less Likely to Receive Treatment Than Men

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

FierceBiotech2d

Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

2don MSN

Key biomarkers identified for predicting disability progression in multiple sclerosis

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Medpage Today on MSN4d

Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...

High-Dose Vitamin D Linked to Lower Disease Activity in CIS

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

PHILADELPHIA.Today on MSN1d

Local Multiple Sclerosis Advocate Honored With State Citation

Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...

4don MSN

Early treatment significantly reduces long-term disability in children with multiple sclerosis, new study finds

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Does Multiple Sclerosis Protect Against Alzheimer's?

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...

MedPage Today1d

Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results